CRD-740 is under clinical development by Cardurion Pharmaceuticals and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase II drugs for Systolic Heart Failure have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CRD-740’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CRD-740 is under development for the treatment of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). It is administered through oral route as tablet formulation. It acts by targeting PDE9.
Cardurion Pharmaceuticals overview
Cardurion Pharmaceuticals is a cardiovascular biotechnology company developing new therapeutics for the treatment of heart failure and cardiovascular diseases. The company is headquartered in Boston, Massachusetts, the US.
For a complete picture of CRD-740’s drug-specific PTSR and LoA scores, buy the report here.